Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture

We have been studying a population of bipotential glial progenitor cells in the perinatal rat optic nerve and brain in an attempt to understand how cells choose between alternative fates in the developing mammalian central nervous system (CNS). This cell population gives rise initially to oligodendrocytes and then to type-2 astrocytes1 both of which apparently collaborate in sheathing axons in the CNS2,3. In vitro studies suggest that oligodendrocyte differentiation is the constitutive pathway of development for the oligodendrocyte-type-2-astrocyte (O-2A) progenitor cell4,5, whereas type-2 astrocyte differentiation depends on a specific inducing protein6. This protein is present in the developing optic nerve when type-2 astrocytes are differentiating and can induce 0-2A progenitor cells in vitro to express glial fibrillary acidic protein (GFAP)6, a marker of astrocyte differentiation7. Here we show that the type-2-astrocyte-inducing protein is similar or identical to ciliary neutrotrophic factor (CNTF)8,9, which promotes the survival of some types of peripheral neurons in vitro8, including ciliary ganglion neurons8,10. This suggests that CNTF, in addition to its effect on neurons, may be responsible for triggering type-2 astrocyte differentiation in the developing CNS

Aspects of the reproductive biology of two archer fishes Toxotes chatareus, (Hamilton 1822) and Toxotes jaculatrix (Pallas 1767)

Various aspects of the reproductive biology of two archer fishes Toxotes chatareus and Toxotes jaculatrix were studied to describe gonad development, spawning season, sex ratio, and fecundity. Spawning season was assessed using monthly changes in gonadosomatic index (GSI) and histological inspection of the gonads. Both species exhibit two modes of oocytes; a mode of small primary growth oocytes and a single mode that increases with size as oocytes sequester vitellogenin and undergo maturation, showing the synchronous oocyte development typical of total spawners. Based on GSI values and advanced stages of oocyte maturity, T. chatareus and T. jaculatrix, females appear to spawn from November to December. The average fecundity of female T. chatareus was 55 000 ± 5538 eggs, and T. jaculatrix was 50 000 ± 3440 eggs; fecundity ranged from 20 000 to 150 000 eggs for both species, with relative fecundities of 600 to 1100 eggs/g body weight, and a mean value of 800 ± 32 for T. chatareus; relative fecundity ranged from 500 to 1100 with a mean value of 700 ± 23 for T. jaculatrix. Sex ratio, defined as the proportion of males to females, was 2. 2 and 2. 5 in T. chatareus and T. jaculatrix, respectively. The apparent abundance of males in samples could be due to females being positioned lower in the water column and therefore being sampled less frequently. Our results indicate that in both species, spawning occurs between the months of November and December during the monsoon season, which provides the mangrove coastal waters inhabited by these species with an abundance of food resources and additional floodplain nursery habitat for larvae and juveniles

Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review

Cell therapy (CTh) is a promising novel therapy for myocardial infarction (MI) and ischemic cardiomyopathy (iCMP). Recognizing adverse events (AE) is important for safety evaluation, harm prevention and may aid in the design of future trials. To define the prevalence of periprocedural AE in CTh trials in MI and iCMP. A literature search was conducted using the MEDLINE database from January 1990 to October 2010. Controlled clinical trials that compared CTh with standard treatment in the setting of MI and/or iCMP were selected. AE related to CTh were analyzed. A total of 2,472 patients from 35 trials were included. There were 26 trials including 1,796 patients that used CTh in MI and 9 trials including 676 patients that used CTh in iCMP. Periprocedural arrhythmia monitoring protocols were heterogeneous and follow-up was short in most of the trials. In MI trials, the incidence of periprocedural adverse events (AE) related to intracoronary cell transplantation was 7.5 % (95 % CI 6.04-8.96 %). AE related to granulocyte colony-stimulating factor (GCS-F) used for cell mobilization for peripheral apheresis was 16 % (95 % CI 9.44-22.56 %). During intracoronary transplantation in iCMP, the incidence of periprocedural AE incidence was 2.6 % (95 % CI 0.53-4.67 %). There were no AE reported during transepicardial transplantation and AE were rare during transendocardial transplantation. The majority of periprocedural AE in CTh trials in MI occurred during intracoronary transplantation and GCS-F administration. In iCMP, periprocedural AE were uncommon. Avoiding intracoronary route for CTh implantation may decrease the burden of periprocedural AE. Standardization of AE definition in CTh trials is needed